Effects of Aortic Valve Replacement on Myocardial T1 Values in Severe Aortic Valve Stenosis

Launched by RIGSHOSPITALET, DENMARK · May 30, 2022

Keywords

ClinConnect Summary

This clinical trial is studying how aortic valve replacement (AVR) affects heart tissue changes in patients with severe aortic valve stenosis, a condition where the heart's aortic valve becomes narrow and makes it harder for blood to flow. The researchers want to see if the amount of heart muscle damage, known as myocardial fibrosis, improves after surgery and how different factors may influence this change. They will use a special imaging technique called T1 mapping to measure heart muscle health before and one year after the surgery.

To participate in the trial, you need to be at least 18 years old and diagnosed with severe aortic valve stenosis. However, if you have a significantly weakened heart function or certain other heart conditions, you may not be eligible. If you join, you'll undergo heart imaging and clinical evaluations before your surgery and again after a year. This research aims to help doctors determine the best timing for aortic valve replacement in patients, ensuring that more people can receive timely and effective treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18 years
• • Severe aortic valve stenosis (Vmax \> 4 m/s and/or mean gradient \>40 mmHg)
• Exclusion Criteria:
• • Reduced left ventricular ejection fraction (\<50%)
• • More than mild left-sided valvular insufficiency
• • Previous or planned primary coronary intervention (PCI) or coronary artery by-pass grafting (CABG)
• • Persistent atrial fibrillation
• • Contraindications for CMR (pregnancy, severe claustrophobia, magnetic metallic implants)
• • Pacemaker/ICD